AU2003240437A1 - Use of dimethyl sulfone as isotonicity agent - Google Patents

Use of dimethyl sulfone as isotonicity agent

Info

Publication number
AU2003240437A1
AU2003240437A1 AU2003240437A AU2003240437A AU2003240437A1 AU 2003240437 A1 AU2003240437 A1 AU 2003240437A1 AU 2003240437 A AU2003240437 A AU 2003240437A AU 2003240437 A AU2003240437 A AU 2003240437A AU 2003240437 A1 AU2003240437 A1 AU 2003240437A1
Authority
AU
Australia
Prior art keywords
dimethyl sulfone
isotonicity agent
isotonicity
agent
sulfone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003240437A
Inventor
Per Balschmidt
Svend Havelund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003240437A1 publication Critical patent/AU2003240437A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2003240437A 2002-06-27 2003-06-23 Use of dimethyl sulfone as isotonicity agent Abandoned AU2003240437A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201007 2002-06-27
DKPA200201007 2002-06-27
PCT/DK2003/000418 WO2004002534A1 (en) 2002-06-27 2003-06-23 Use of dimethyl sulfone as isotonicity agent

Publications (1)

Publication Number Publication Date
AU2003240437A1 true AU2003240437A1 (en) 2004-01-19

Family

ID=29797017

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003240437A Abandoned AU2003240437A1 (en) 2002-06-27 2003-06-23 Use of dimethyl sulfone as isotonicity agent

Country Status (3)

Country Link
EP (1) EP1539244A1 (en)
AU (1) AU2003240437A1 (en)
WO (1) WO2004002534A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1673102A1 (en) * 2003-10-17 2006-06-28 Crucell Holland B.V. Treatment and prevention of decubitus
CN1939534B (en) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 Externally-applied preparation containing human growth incretion or human granular leukocyte macrophage stimulus factor for treating injury ulceration
WO2007108505A1 (en) * 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
EP2328570A4 (en) * 2008-08-15 2012-10-24 Livionex Inc Method and formulation for treating adverse biological conditions
DK2552410T3 (en) 2010-03-31 2019-02-18 Stabilitech Biopharma Ltd PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
CN102892427A (en) 2010-03-31 2013-01-23 稳定性科技有限公司 Excipients for stabilising viral particles, polypeptides or biological material
ES2757591T3 (en) 2010-03-31 2020-04-29 Stabilitech Biopharma Ltd Stabilization of viral particles
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752658B2 (en) * 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
EP1052288A1 (en) * 1999-05-10 2000-11-15 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
JP2005526009A (en) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ Novel glucose-dependent insulin

Also Published As

Publication number Publication date
EP1539244A1 (en) 2005-06-15
WO2004002534A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
AU2003259735A1 (en) Small-mer compositions and methods of use
AU2003225705A1 (en) Cytidine analogs and methods of use
AU2003294778A1 (en) Novel use of lycopene
AU2003209400A1 (en) Multiple degree of freedom interferometer
AU2003225669A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003213673A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003269092A1 (en) Computation of contour
AU2002258559A1 (en) Skin care compositions
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003220968A1 (en) Anti-inflammatory agent
AU2003230952A1 (en) Treatment of mucositis
AU2003226487A1 (en) Formulation
AU2003244836A1 (en) Suspending agent
AU2003240437A1 (en) Use of dimethyl sulfone as isotonicity agent
AU2003289207A1 (en) Anti-inflammatory agent
AU2003273803A1 (en) Use of triptans as antiviral agents
AU2003300543A1 (en) Slow release formulation of clarithromycin
AU2003207181A1 (en) Microorganism-trapping agent
AU2003298725A1 (en) Preparation of metallotexaphyrins
AU2003238835A1 (en) HUMAN COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1 (hCARM1)
AU2003205963A1 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
AU2003201853A1 (en) Skin preparations for external use
AU2003238034A1 (en) Novel use of imidazotriazinones
AU2003265500A1 (en) Hair spray composition
AU2003245524A1 (en) Cryosurgery compositions and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase